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Abstract
Introduction: To assess the efficacy and safety of the interleukin-1 receptor (IL-1R) inhibitor anakinra in adult
patients with refractory Still’s disease.
Methods: Twenty-five patients (13 males and 12 females, median age 32 years, median disease duration seven
months) with Still’s disease were treated with subcutaneous injections of anakinra (100 mg/day). Treatment was
given as adjunct therapy in 16 patients and as standalone in 9 patients for a median time of 15 months (range
1.5-71). The clinical and laboratory parameters during follow-up were recorded.
Results: In 84% of patients the clinical activity resolved completely within a few days (median time 0.2 months),
and response was maintained until the last visit in all but one patient. A complete response of all disease-related
symptoms (clinical and laboratory) occurred subsequently within a median time of three months in 80% of
patients. A partial clinical and laboratory improvement was shown in 12% and 16% of patients, respectively. The
Visualized Analogue Scale and Health Assessment Questionnaire scores significantly decreased during treatment.
The proportion of patients achieving the American College of Rheumatology 20 (ACR20) score (20% improvement)
was 82% at one month and improved to 100% at one year. The mean oral corticosteroid dose was significantly
reduced at each visit. Anakinra was discontinued due to unresponsiveness in one patient and due to relapsing
disease in another. Treatment was also withdrawn in three patients with severe skin reactions (urticaria). Seven
patients experienced an infection during follow-up.
Conclusions: The rapid and sustained response in the majority of our patients encourages the use of anakinra in
adults with Still’s disease.
Introduction
Still’s disease is a rare systemic inflammatory disorder of
unknown etiology characterized by quotidian spiking
fevers, evanescent rash, arthritis, and elevated acute-phase
reactants in the serum linked to alterations in the produc-
tion of proinflammatory cytokines. Treatment has been
empirical, with data on treatment efficacy extrapolated
from case reports and small scale retrospective studies.
Non-steroidal anti-inflammatory drugs and corticosteroids
have been a mainstay for decades in treating adults with
Still’s disease; however, resistance to treatment as well as
drug-related complications have been observed [1,2].
Immunosuppressants, mainly methotrexate (MTX), used
as steroid-sparing drugs, have shown modest efficacy
across studies [3,4]. In recent years, advances in the under-
standing of the role of cytokines in the disease pathogen-
esis has led to the application of anticytokine agents, often
in combination with traditional immunosuppressive drugs,
which opened a new, promising horizon in the treatment
of adult Still’s disease. Hence, TNF-a inhibitors have been
successfully employed in some cases unresponsive to con-
ventional treatment [5-10]. More recently, IL-1 activity
has been linked to the pathogenesis of Still’s disease as
well as other systemic inflammatory diseases characterized
in part by recurrent fevers, leucocytosis, anemia, and ele-
vated acute-phase proteins, because rapid and sustained
resolution of systemic and local inflammation is observed
upon specific blockade of IL-1 receptors (IL-1R) [11]. The
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anakinra, a recombinant form of the human IL-1R antago-
nist that inhibits IL-1 binding on its receptor approved for
use in rheumatoid arthritis, appears to be promising treat-
ment in patietns with refractory Still’s disease [2,12-19].
Materials and methods
Patient selection and follow up
Twenty-five patients with active Still’s disease (4 had juve-
nile onset and 21 adolescent- or adult-onset disease) resis-
tant to glucocorticosteroids (n = 17), disease-modifying
anti-rheumatic drugs (DMARDs; n = 4), or TNFa inhibi-
tors (n = 4) who received treatment with anakinra were
studied. All patients were diagnosed and followed in one
medical center. All patients fulfilled the Yamaguchi disease
criteria [20]. Patients younger than 18 years old were
excluded from the study.
Information on patients was initially retrieved retrospec-
tively from their medical records. Data were collected just
before the initiation of anakinra treatment, at 1, 3, 6, and
12 months and at the latest follow up. Data included age,
sex, disease duration, number of fulfilled Yamaguchi dis-
ease criteria, immunological profile, systemic symptoms
(fever, rash, lymphadenopathy, hepatosplenomegaly, sero-
sitis, sore throat), tender joint count, swollen joint count,
haematological profile, erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), liver enzymes, and serum
ferritin levels during follow up. The American College of
Rheumatology (ACR) 20, 50, and 70 score (20%, 50%, and
70% improvement in joint disease, respectively) was also
recorded [21]. Moreover, drug-related adverse events were
recorded. After the relevant information was collected,
each patient was contacted to have a final evaluation, per-
formed for all cases by the same physician. Using the
information retrieved from both the medical charts and
the oral evaluation, the exact time-points of partial and
complete response as well as relapse were determined.
The Health Assessment Questionnaire (HAQ), Visual
Analogue Scale (VAS) for the assessment of pain and glo-
bal patient well-being, as well as VAS physician scores
(physician assessment of disease activity) during follow up
were calculated for each patient. Oral informed consent
was obtained in all cases before starting treatment and the
treatment regimen was approved by the hospital ethical
committee.
Assessments and definitions
The effect of anakinra on all clinical and laboratory dis-
ease-related manifestations during follow up was evalu-
ated and drug adverse events were recorded. Moreover,
the proportion of patients with complete clinical
response (CCR) or complete laboratory response (CLR)
and partial clinical response (PCR) or partial laboratory
response (PLR) as well as the time to these events were
determined. Complete response was defined as the com-
plete resolution of all disease-related symptoms, except
for joint erosion [18]. PCR or PLR was defined as
improvement (at least 10% when measurement was feasi-
ble) in one or more related clinical or laboratory, respec-
tively, manifestations, but without complete resolution of
disease activity. Relapse was defined as a worsening in
disease activity requiring switching to another treatment
agent or the addition of another therapy to the underly-
ing medication.
Immunosuppressive treatment
Sixteen of the 25 patients received daily injections of ana-
kinra (100 mg/day) subcutaneously as adjunct therapy
together with a DMARD and nine patients received ana-
kinra as monotherapy. Concomitant medication included
MTX in 13 patients at a median (range) dose of 12.5
(7.5 to 20) mg/week, leflunomide at a low dose (10 mg/
day) in one patient, and cyclosporine A at the dose of
3 mg/kg/day in another one. MTX was given during the
whole follow up in 10 of the 13 patients. In three patients,
MTX was discontinued eight, five, and five months after
remission was achieved. In three other patients, MTX was
added to treatment with anakinra later during follow up.
Two of them started MTX at a disease flare, while the
third one was in remission at MTX initiation. The two
patients treated with either cyclosporine A or leflunomide
as concomitant medication had a short follow up of 1.5
and 3 months. The oral methylprednisolone dose was
slowly tapered during follow up based on the physician’s
assessment of disease activity.
Statistical analysis
Scaled and/or ordinal patient characteristics were com-
pared during follow up using the Wilcoxon test for paired
observations and nominal parameters using the McNemar
test. Time to event analyses were performed according to
the Kaplan-Meier method. Disease outcome was com-
pared between patients receiving and those not receiving
concomitant medication using both the chi squared test
and survival analysis in means of the log-rank test. Results
were considered significant when P value of 0.05 or less.
Analyses were conducted in SPSS version 13 (Chicago,
Illinois, USA). All P values are two-tailed.
Results
Patient characteristics
Twenty-five patients (13 males and 12 females) received
anakinra as adjunct therapy (n = 16) or monotherapy (n =
9) for a median (range) time of 15 (1.5 to 71) months. The
median patient age was 32 (18 to 71) years. The median
disease duration until anakinra treatment initiation was 7
(1 to 228) months and the median number of Yamaguchi
disease criteria fulfilled at baseline was 6 (5 to 8). Three
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patient developed rheumatoid factor positivity during fol-
low up. Oral methylprednisolone was given to all but
three patients at a median dose of 4 (range 0 to 26) mg/
day. The median corticosteroid dose was significantly
reduced at each visit (Table 1) and 12 patients were able
to wean from steroids until the end of follow up.
Clinical and laboratory parameters during follow up
The patient clinical and laboratory characteristics from
baseline until the latest visit are shown in Table 1. Of the
total 25 patients, 20 (80%) had a follow-up time of at least
6 months and 15 patients (60%) had a follow-up time
greater than 1 year as shown in Table 1. A significant
improvement in all investigated parameters was observed
within the first month of treatment (Table 1 and Figure 1)
and at each evaluation during follow up compared with
baseline (P values not shown). When subsequent time-
points were compared with each other, no significant
changes were observed (data not shown) except for hemo-
globin, CRP, and ESR levels which continued to signifi-
cantly improve after the first and up to the third month of
treatment (Table 1). Although the hemoglobin levels sig-
nificantly increased within the first month of treatment,
the number of patients with anemia significantly decreased
at three months (Table 1). A significant decrease in HAQ,
and VAS pain, global and physician scores was demon-
strated within the first month of treatment (Table 1). The
percent of patients achieving the ACR20 score was 82% at
one month and improved to 100% at one year. The
ACR50 and ACR70 scores at one year were 93% and 87%,
respectively. None of the patients presented the hemopha-
gocytic syndrome complicating Still’s disease. Renal amy-
loidosis was suspected in one patient with proteinuria
(1.5 g in 24-hour urine collection), absence of active urine
sediment, normal renal function, and absence of other
underlying medical conditions that might cause renal
damage. The amount of proteinuria did not improve dur-
ing follow up, although other clinical and laboratory para-
meters normalized until the latest visit. None of the
patients died.
Complete and partial clinical response
In 21 (84%) of the 25 patients, clinical activity resolved
completely and response was maintained until the last
visit in all but one. Three (12%) of the 25 patients had
partial response and presented with arthralgias (n = 2)
or arthritis and intermittent fever (n = 1) at the end of
follow up. One patient (4%) with prominent articular
disease did not show any improvement within four
months, was assigned to another treatment, and was
withdrawn from the study (Patient 6, Table 2). In all but
one patient with CCR, laboratory parameters were
normal (Patient 5, Table 2). In contrast, all patients with
PCR had persisting biological activity (Table 2). In survi-
val analysis, a complete resolution of clinical activity was
observed within a few days of the first injection in most
patients (median time 0.2 months, range 0.01 to 8
months), while PCR was achieved within a few days
(0.01 month) in one patient and at one month in the
other two.
Complete and partial laboratory response
At the end of follow up, in 20 (80%) of the 25 patients
laboratory parameters returned to normal, 4 (16%) showed
a partial response, whereas 1 patient (4%) remained with
active disease (Table 2). Disease was clinically silent in all
patients with CLR. At the end of follow up, high ferritin
levels and anemia were most commonly found among the
five patients with persisting biological activity. More speci-
fically, persisting abnormalities included high ferritin levels
(n = 4), anemia (n = 4), leucocytosis (n = 3), thrombocyto-
sis (n = 2), high CRP levels (n = 2), elevated ESR (n = 3),
and elevated liver enzymes (n = 2; Table 2). All but one
patient with serological activity were also clinically active
(Patient 4, Table 2). A complete response of all biological
disease-related symptoms occurred within a median time
of 3 months (range 1 to 10 months), whereas a partial
improvement in laboratory parameters was observed in
the first month of treatment in all four patients with PLR
at the end of follow up.
Relapse
A disease exacerbation occurred in three patients (12%).
One patient in PCR and PLR groups deteriorated at
four months of treatment. The interval between spiking
fever episodes decreased to daily events and articular
involvement worsened (Patient 2, Table 2). Two months
later immunosuppressive treatment was switched to
another drug agent and the patient was withdrawn from
the study. In another patient in PCR and PLR, the fever
and rash reappeared, while articular involvement dete-
riorated five months after treatment initiation. In paral-
lel, white blood cell (WBC) count, ferritin levels, and
liver enzymes increased. MTX was started in addition to
anakinra at a mean dose of 18.75 mg/week and the
patient went into complete clinical and laboratory
remission three and four months later, respectively
(Patient 5, Table 2). A third patient, in complete remis-
sion of all disease-related manifestations for nine
months, reduced anakinra to alternate day dosing and
presented fever, rash, leucocytosis, and elevation of
acute-phase reactants four months later. He was started
on daily injections again combined with MTX 15 mg/
week and went into complete disease remission within
one month (Patient 7, Table 2).
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Three patients developed a severe urticarial reaction
after the first months of treatment (one patient at 1.5
month and two patients at 3 months) and discontinued
therapy. Seven patients (28%) developed infections (one
trachiobronchitis, one H1N1 virus infection of the upper
respiratory tract, one gastroenteritis with fever, one soft
tissue abscess, and three lower urinary tract infections),
which led to a transient discontinuation of the immuno-
suppressive treatment. The transient withdrawal of
Table 1 Patient clinical and laboratory characteristics during follow up
At
baseline
(n = 25)
At 1
month *
(n = 25)
At 3
months **
(n = 24)
At 6
months
(n = 20)
At 12
months
(n = 18)
At latest follow up
(n = 15)
Fever 24 (96) 1 (4) 1 (4) 2 (10) 0 0
Rash 16 (64) 0 0 1 (5) 0 0
Lymphadenopathy 14 (56) 0 0 1 (5) 0 0
Arthralgias 22 (88) 9 (36) 5 (21) 2 (10) 0 0
TJC 12 (0-38) 0 (0-24) 0 (0-24) 0 (0-34) NA *** NA ***
Arthritis 15 (60) 2 (8) 2 (8) 2 (10) 0 0
SJC 1 (0-15) 0 (0-5) 0 (0-5) 0 (0-34) NA *** NA ***
Hepatosplenomegaly 11 (44) 0 0 1 (5) 0 0
Sore throat 14 (56) 1 (4) 1 (4) 1 (5) 0 0
Serositis 5 (20) 0 0 0 0 0
Anemia ‡
(Hb < 12 g/dl for females and < 13.5 g/dl
for males)
16 (64) 10 (40) 5 (21) 2 (10) 0 0
Hb (g/dl) 11.8 (8.5-14.4) 12.7 (8.7-16) 13.1 (9.8-15.3) 14 (10-16) 13.7 (12-15.8) 14 (12.3-15.4)
Leucocytosis
(> 10,000/mm
3)
21 (84) 9 (36) 5 (21) 3 (15) 0 0
WBC (× 10
3/mm
3) 16.8 (4.8-33.6) 8.2 (3-20.6) 6.9 (2.8-15) 6.5 (3.5-18.4) 6.3 (3.2-9.8) 6.5 (4-9)
Thrombocytosis
(> 450,000/mm
3)
8 (32) 3 (12) 2 (8) 1 (5) 0 0
PLTs (× 10
3/mm
3) 378 (134-554) 228 (156-555) 251 (160-556) 215 (165-511) 236 (145-334) 210 (121-274)
Elevated CRP (> 10 mg/dl) 25 (100) 8 (32) 6 (25) 4 (20) 0 0
CRP (mg/dl) 111 (19-318) 5.4 (0.1-200) 6 (0.2-107) 3.6 (0.8-119) 2 (0.1-10) 3.5 (0.4-9)
Elevated ESR (> 30 mm/h) 24 (96) 6 (24) 2 (8) 1 (5) 0 0
ESR (mm/h) 75 (26-120) 20 (2-130) 11.5 (2-72) 10 (2-105) 6 (2-23) 4 (1-15)
High ferritin levels (> 300 ng/ml) 24 (96) 7 (28) 4 (17) 3 (15) 0 0
Ferritin (ng/ml) 3000 (192-88126) 217 (47-6413) 111 (24-7700) 165 (9-3163) 59 (10-209) 58 (41-124)
Elevated liver enzymes 15 (60) 6 (24) 1 (4) 2 (10) 2 (11) 0
HAQ 2.19 (0.25-3) 0.31 (0-2.25) 0 (0-1.44) 0 (0-3) 0 (0-1.25) 0 (0-1.25)
VAS pain 2.4 (0.6-3) 0 (0-2.4) 0 (0-2.7) 0 (0-2.7) 0 (0-1.5) 0 (0-1.5)
VAS global 2.25 (0.9-3) 0.3 (0-2.4) 0 (0-2.7) 0 (0-2.7) 0 (0-1.5) 0 (0-1.5)
VAS physician 1.8 (0.9-2.7) 0.3 (0-1.8) 0 (0-2.4) 0 (0-2.4) 0 (0-0.3) 0 (0-0.3)
ACR20 NA *** 18/22 (82) 17/21 (81) 15/17 (88) 15/15 (100) 13/13 (100)
ACR50 NA *** 15/22 (68) 16/21 (76) 15/17 (88) 14/15 (93) 13/13 (100)
ACR70 NA *** 14/22 (64) 15/21 (71) 13/17 (76) 13/15 (87) 12/13 (92)
Methylprednisolone oral dose † (mg/d) 18 (0-48) 14 (0-40) 8 (0-32) 7 (0-24) 0.5 (0-14) 0 (0-8)
* Significant comparisons of clinical and laboratory parameters at one month vs. baseline: fever P < 0.001, rash P < 0.001, lymphadenopathy P < 0.001, arthralgias
P < 0.001, TJC P < 0.001, arthritis P < 0.001, SJC P = 0.01, hepatosplenomegaly P = 0.002, sore throat P < 0.001, serositis P = 0.063, Hb (g/dl) 0.007, leucocytosis
P = 0.001, WBC (× 10
3/mm
3) P < 0.001, thrombocytopenia P = 0.063, PLTs (× 10
3/mm
3) P = 0.03, elevated CRP P < 0.001, CRP (mg/dl) P = 0.001, elevated ESR P <
0.001, ESR (mm/h) P = 0.013, high ferritin levels P = 0.004, ferritin (ng/ml) P = 0.002, elevated liver enzymes P = 0.021, HAQ score P < 0.001, VAS pain score P <
0.001, VAS global score P < 0.001, VAS physician score P < 0.001.
‡ Anemia at one month vs. baseline P = 0.375, at three months vs. baseline P = 0.008.
** Significant comparisons at three months vs. one month: CRP (mg/dl) P = 0.028, ESR (mm/h) P = 0.04, Hb (g/dl) P = 0.042.
† Significant reduction of the oral methylprednisolone dose during follow-up: at one month vs. baseline P = 0.001, at three months vs. one month P = 0.001, at
six months vs. three months P = 0.015, at 12 months vs. six months P = 0.005, at end vs. 12 months P = 0.043.
*** NA, not applicable
ACR, American College of Rheumatology; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; Hb, hemoglobin;
PLTs, platelets; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale; WBC, white blood cells.
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one patient; however, symptoms automatically resolved
after drug reinstitution. One patient receiving MTX as
concomitant medication had a slight increase in liver
enzymes later during follow up (less than a two-fold
increase compared with normal values) with no sign of
disease flare considered as drug toxicity. Five patients
had a local hypersensitivity reaction at the site of
injection.
Anakinra as adjunct therapy vs. monotherapy
When disease outcome was compared between patients
receiving and those not receiving concomitant medica-
tion with a DMARD, no significant differences were
demonstrated in the achievement of CCR, PCR, CLR,
PLR, and relapse both in means of the chi squared test (P
=1 . 0 0 )a n ds u r v i v a la n a l y s i s( P≥0.10 in all comparisons;
data not shown). Moreover, the number of tender and
swollen joints at baseline and during follow up were
comparable (P > 0.30 in all comparisons). The number of
drug-related adverse events did not significantly differ
between patients treated with a DMARD and those who
received anakinra as monotherapy (P = 1.00).
Anakinra dosing reduction and long-term follow up
Seven of the 20 patients in complete disease remission
increased the interval between anakinra injections by
receiving one dose every other day during the last
months of follow up (median duration 6 months, range 4
to 30 months). The patients were in remission for a med-
i a nt i m eo f1 2m o n t h s( 7t o2 5m o n t h s )b e f o r ea n a k i n r a
dosing tapering. Only one of these patients relapsed four
months after anakinra dosing reduction (see paragraph
about relapse). In eight patients in complete remission
(including three of the above patients) treatment was dis-
continued. Two of them relapsed one month after
Figure 1 Graphical presentation of the median values and 25
th/75
th percentiles of (a) CRP levels, (b) ferritin levels, (c) WBC count, and
(d) Hb levels during follow up. In a and b the logarithmic values of C-reactive protein (CRP) and ferritin levels are provided. Hb, hemoglobin;
WBCs, white blood cells.
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in remission after a median time period of 6.5 months (1
to 60 months) of treatment discontinuation.
Discussion
In the present study we assessed the efficacy and safety
of the IL-1R inhibitor anakinra in adult patients with
refractory Still’s disease. To our knowledge, this is the
largest series reported in literature, because previous
reports consist of smaller patient series as well as case
reports [2,13-19,22].
In agreement with previous data, we observed a rapid
and sustained response to anakinra treatment in the
majority of patients [2,13-19]. A dramatic improvement
in all disease-related manifestations was evident from the
first month of treatment. Complete resolution of clinical
symptoms occurred within a few days after the initiation
of treatment and was followed by normalization of acute-
phase reactants, hematological parameters, and biochem-
ical markers of systemic disease within the first three
months. According to the already reported literature, the
time to complete resolution of clinical activity varied
from a few hours after the first injection up to two
months of treatment, with most cases remitting within
some days, while laboratory markers returned to normal
subsequently within one week to two months [13-19]. In
the two largest already published series of 15 and 8
patients, respectively, disease activity completely resolved
in 60% and 90% of patients, respectively, whereas no effi-
cacy was reported in 13% of patients in the first study
[18,19]. In accordance with our data, persisting clinical
activity was expressed with arthralgias or fever. Elevated
CRP, ESR, and ferritin levels were the abnormal labora-
tory markers in patients with residual serological activity.
In line with our observations, Maier et al. reported ane-
mia and high ferritin levels as disease markers that nor-
malized at last [17]. In our study, clinical activity resolved
completely in 84% and laboratory parameters returned to
normal in 80% of patients, while 4% did not show any
response to treatment. In only two patients, anakinra was
discontinued because of inadequate response. It is of
note that three of four patients in partial response had a
short follow-up time of 1.5 to 3 months because of an
early drug withdrawal. Thus, a potential delayed response
i nt h o s ep a t i e n t si ft h e yw e r et r e a t e df o ral o n g e rt i m e
period cannot be excluded.
The great efficacy of the IL-1R inhibitor points toward
the important role of IL-1 in the pathophysiological
Table 2 Characteristics of patients with inadequate response to treatment or relapse
Pt Age HAQ
at t0
Months of
treatment/
withdrawal
DMARD/mean
GC oral dose
(mg/d)
Previous
treatment
PCR/CCR
(months
to
event)
Persisting
clinical
symptoms
PLR/CLR
(months
to
event)
Persisting
biological
activity
Relapse (months to
event)
1 24 3 3/drug toxicity CyA/16 GC PCR (1) Arthralgias PLR (1) ↑ WBC,
↑ Ferritin,
↑ Liver
enzymes
No
2 16 1.25 6/disease flare MTX/8 MTX+GC
+ETN
PCR (1) Fever, Arthritis PLR (1) Anemia,
↑ WBC,
↑ PLTs,
↑ CRP,
↑ ESR,
↑ Ferritin
Yes (4)
3 56 2.5 3/drug toxicity None/0 GC PCR
(0.01)
Arthralgias PLR (1) Anemia,
↑ Ferritin
No
4 64 1.5 1.5/drug toxicity LEF/3 MTX+GC CCR (1) - PLR (1) Anemia,
↑ ESR
No
5 48 2.5 14/follow up end MTX for the last 8
months/18.25
GC PCR
(0.5)/CCR
(8)
Arthralgias/
Arthritis
PLR (1)/
CLR (9)
↑ WBC,
↑ CRP
Yes (5)
6 32 1.8 4/no response MTX/4 MTX+GC
+ETN,
then ADA
No
response
Arthralgias/
Arthritis
No
response
Anemia,
↑ WBC,
↑ PLTs,
↑ CRP,
↑ ESR,
↑ Ferritin
-
7 49 3 15/follow up end MTX for the last 2
months/18.6
GC CCR (0.2
and 13.5)
- CLR (1
and 14)
- Yes (13 e.g. 4 months
after reducing anakinra
dosing)
ADA, adalimumab; CCR, complete clinical response; CLR, complete laboratory response; CRP, C-reactive protein; CyA, cyclosporine A; DMARD, disease-modifying
anti-rheumatic drug; ESR, erythrocyte sedimentation rate; ETN, etanercept; F, female; GC, glucocorticosteroids; HAQ, health assessment questionnaire; LEF,
leflunomide; M, male; MTX, methotrexate; PCR, partial clinical response; PLR, partial laboratory response; PLTs, platelets; WBC, white blood cells.
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IL-1 levels have been detected in active untreated dis-
ease [13,15]. Kötter et al demonstrated high IL-1 and
IL-18 in active disease, whereas moderately high TNF-a
and IL-6 levels, that significantly fell following treatment
with the IL-1R inhibitor [15]. Similarly, Fitzgerald et al.
demonstrated high IL-1a, IL-1b, IL-1RA, IL-6, and IL-18
serum levels prior to the first injection of anakinra,
w h i l ead r a m a t i cr e d u c t i o ni nt h el e v e l so fI L - 6 ,I L - 1 8 ,
and IL-1RA accompanied the disease activity resolution
upon treatment initiation [13]. An increase in the serum
proinflammatory cytokine levels was observed when
therapy was stopped. However, the group of partial
responders and non-responders might be suggestive of
disease subtype heterogeneity and likely reflects different
roles of cytokines and pathological processes in these
patients [23,24]. In fact, one patient in the present study
with prominent articular involvement without clinical
signs of systemic disease, did not improve during ana-
kinra treatment.
Relapses under anakinra are rarely reported [13,19].
However, studies with a large number of patients and a
long period of follow up are still pending. In this report,
the effects of anakinra treatment were sustained until
the latest visit in all but one complete responder. This
patient relapsed after reducing the frequency of drug
injections. Two other patients who experienced a disease
flare were in partial response.
There is no clear evidence whether the use of anakinra
in combination with a DMARD, such as MTX, improves
its efficacy. In our series, either the overall efficacy or the
articular disease were both comparable between patients
receiving anakinra as adjunct and those as monotherapy.
Similarly, in the report by Lequerré et al, DMARD use
was not particularly different in the complete response
vs. the non-responder cohort [18]. However, long-term
data are missing. Our study provides evidence that ana-
k i n r am o n o t h e r a p ym a yb ea ne f f e c t i v et h e r a p e u t i c
option in some patients, whereas combination with a
DMARD may be necessary when residual or recurrent
disease activity is present. In fact, recurrent disease in the
form of arthralgias/arthritis, fever, rash, and acute inflam-
matory response was effectively controlled by the addi-
tion of MTX to anakinra treatment, as also previously
reported [13,19].
Regarding concomitant oral corticosteroid usage, ana-
k i n r aw a ss h o w nt ob ea ne f f e c t i v es t e r o i d - s p a r i n g
agent. In agreement with the already reported literature,
the use of anakinra allowed fast steroid tapering in
responders and total discontinuation of steroid intake in
approximately half of them [13,14,17-19]. Moreover,
four patients did not require any corticosteroid therapy
during the whole follow up.
The optimal treatment duration with anakinra is
unknown. An interesting issue is whether the number of
anakinra injections per week can be decreased in respon-
ders. Gradual reduction of anakinra dosing after a median
of 12 months on remission seemed to be safe in our series,
because only one of seven patients under alternate day
treatment relapsed. Safe increasing of the time interval
between anakinra applications has been also reported by
Maier et al., whereas Kötter et al. described recurrence of
disease activity after reducing anakinra to alternate day
dosing [15,17]. In responders, total drug discontinuation
led to the recurrence of disease activity in two of eight of
our patients, while the rest of patients remained in com-
plete remission for a median time of 6.5 months. Thus,
remission may be maintained in some patients after drug
discontinuation. However, given the small number of
patients and the relatively short follow up after drug with-
drawal, any conclusions can only be interpreted with
caution.
In regard to toxicity, anakinra was safe and well toler-
ated in all but three patients who discontinued therapy
because of severe urticarial-like skin reactions and one
patient with severe trachiobronchitis. Lequerré et al.
reported anakinra withdrawal in two patients who devel-
oped skin rash at first and third month of treatment,
whereas severe systemic inflammatory response syndrome
has been also described as an IL-RA therapy complication
[18,22]. Infections were not rare in our patients (28%).
The observed rates were similar with those described pre-
viously [18]. Finally, local pain or reactions to injections
have been frequently reported in literature [15,16,18,19].
The rebound of disease activity following transient cessa-
tion of IL-1RA therapy due to opportunistic infections,
was noticed in one of our patients as well as in other pub-
lished cases; however, disease activity resolved after drug
reinstitution in all of them [13,16,19].
Compared with TNFa inhibitors or MTX monother-
apy, anakinra seems to have a more rapid and efficient
effect in adult patients with Still’s disease. Response rates
in the largest series using anti-TNFs and/or MTX were
lower than in the present study ranging between 25% and
69%, whereas worsening of disease and/or exacerbations
were also reported [3-6]. Compared with anakinra, the
response was delayed with most cases remitting after two
weeks of treatment and up to 16 weeks. However, most
promising results have been reported in smaller series
[9,10]. At this point, it is worth presenting unpublished
data on a historical control of adult patients with Still’s
disease followed up in our department and treated with
TNF inhibitors (infliximab n = 4, etanercept n = 2, adali-
mumab n = 1), and (n = 5) or MTX (n = 6). In accor-
d a n c ew i t hp r e v i o u s l yr e p o r t e dd a t a ,5 4 %o fp a t i e n t s
went into complete disease remission, whereas 43% of
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response was four months (range 0.5 to 6 months), while
laboratory parameters returned to normal after a median
time of four months (range 0.5 to 10 months). Sequential
treatment with different anti-TNFs in five of our patients
did not change drug efficacy, whereas two of four
patients who received anakinra due to unresponsiveness
to anti-TNFs went into remission.
Finally, our results should be interpreted in the con-
text of potential limitations. The present study was not
prospectively designed. Therefore, detailed information
on the drug use before the initiation of anakinra was
not always available. Moreover, the relatively small num-
ber of patients limits the statistical power of the study.
Thus, no definite conclusions can be drawn regarding
the efficacy of anakinra as adjunct vs. monotherapy.
Additionally, more than one third of our cohort had a
duration of follow up shorter than one year. Neverthe-
less, the rapid clinical response as well as the long-last-
ing efficacy together with the steroid-sparing effect and
the favorable safety profile in most of our patients
encourages further use of anakinra in adults with Still’s
disease.
Conclusions
Based on these observations, we suggest that blocking
IL-1R as monotherapy or in combination with a
DMARD may become the treatment of choice for
patients with refractory Still’s disease.
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